Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

Authors: Jungwhoi Lee, Song-I Han, Jeong-Hun Yun, Jae Hoon Kim

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Pancreatic cancer is one of the most dangerous cancers and is associated with a grave prognosis. Despite increased knowledge of the complex signaling networks responsible for progression of pancreatic cancer, many challenging therapies have fallen short of expectations. In this study, we examined the anti-migratory effect of quercetin 3-O-glucoside in epidermal growth factor–induced cell migration by inhibiting EGF receptor (EGFR) signaling in several human pancreatic cancer cell lines. Treatment with quercetin, quercetin 3-O-glucoside, and quercetin 7-O-glucoside differentially suppressed epidermal growth factor–induced migration activity of human pancreatic cancer cells. In particular, quercetin 3-O-glucoside strongly inhibited the infiltration activity of pancreatic cancer cells in a dose-dependent manner. Furthermore, quercetin 3-O-glucoside exerted the anti-migratory effect even at a relatively low dose compared with other forms of quercetin. The anti-tumor effects of quercetin 3-O-glucoside were mediated by selectively inhibiting the EGFR-mediated FAK, AKT, MEK1/2, and ERK1/2 signaling pathway. Combinatorial treatment with quercetin 3-O-glucoside plus gemcitabine showed the synergistic anti-migratory effect on epidermal growth factor–induced cell migration in human pancreatic cancer cell lines. These results suggest that quercetin 3-O-glucoside has potential for anti-metastatic therapy in human pancreatic cancer.
Literature
1.
go back to reference Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.
2.
go back to reference Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.CrossRefPubMed Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.CrossRefPubMed
3.
4.
go back to reference Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Sci World J. 2010;10:1947–57.CrossRef Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Sci World J. 2010;10:1947–57.CrossRef
5.
go back to reference Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology. 2001;48:933–8.PubMed Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology. 2001;48:933–8.PubMed
6.
go back to reference Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol : Int J Published British Ind Biol Res Assoc. 1995;33:1061–80.CrossRef Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol : Int J Published British Ind Biol Res Assoc. 1995;33:1061–80.CrossRef
7.
8.
go back to reference Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83:6–15.CrossRefPubMed Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83:6–15.CrossRefPubMed
9.
go back to reference Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38.CrossRefPubMed Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38.CrossRefPubMed
10.
go back to reference Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via g2/m arrest and induction of apoptosis. Drug Metab Disposition: Biol Fate Chem. 2006;34:296–304.CrossRef Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via g2/m arrest and induction of apoptosis. Drug Metab Disposition: Biol Fate Chem. 2006;34:296–304.CrossRef
11.
go back to reference Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med: eCAM. 2011;2011:591356.CrossRefPubMedPubMedCentral Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med: eCAM. 2011;2011:591356.CrossRefPubMedPubMedCentral
12.
go back to reference Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315–25.CrossRefPubMed Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315–25.CrossRefPubMed
13.
go back to reference Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-o-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35:414–6.PubMed Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-o-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35:414–6.PubMed
14.
go back to reference Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed
16.
go back to reference Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett. 2011;309:145–50.CrossRefPubMed Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett. 2011;309:145–50.CrossRefPubMed
17.
go back to reference Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, et al. Blockade of vegf-a suppresses tumor growth via inhibition of autocrine signaling through fak and akt. Cancer Lett. 2012;318:221–5.CrossRefPubMed Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, et al. Blockade of vegf-a suppresses tumor growth via inhibition of autocrine signaling through fak and akt. Cancer Lett. 2012;318:221–5.CrossRefPubMed
18.
go back to reference Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig. 1992;90:1352–60.CrossRefPubMedPubMedCentral Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig. 1992;90:1352–60.CrossRefPubMedPubMedCentral
19.
go back to reference Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Czyzewska J. Expression of egf and egfr strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–404.PubMed Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Czyzewska J. Expression of egf and egfr strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–404.PubMed
20.
go back to reference Angst E, Park JL, Moro A, Lu QY, Lu X, Li G, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42:223–9.CrossRefPubMedPubMedCentral Angst E, Park JL, Moro A, Lu QY, Lu X, Li G, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42:223–9.CrossRefPubMedPubMedCentral
21.
go back to reference Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–61.PubMed Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–61.PubMed
22.
go back to reference Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22:1615–27.PubMed Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22:1615–27.PubMed
23.
go back to reference Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-o-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 2000;33:667–76.CrossRefPubMed Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-o-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 2000;33:667–76.CrossRefPubMed
24.
go back to reference Du XY, Huang J, Xu LQ, Tang DF, Wu L, Zhang LX, et al. The proto-oncogene c-src is involved in primordial follicle activation through the pi3k, pkc and mapk signaling pathways. Reprod Biol Endocrinol : RB&E. 2012;10:58.CrossRef Du XY, Huang J, Xu LQ, Tang DF, Wu L, Zhang LX, et al. The proto-oncogene c-src is involved in primordial follicle activation through the pi3k, pkc and mapk signaling pathways. Reprod Biol Endocrinol : RB&E. 2012;10:58.CrossRef
25.
go back to reference Roby KF, Son DS, Taylor CC, Montgomery-Rice V, Kirchoff J, Tang S, et al. Alterations in reproductive function in src tyrosine kinase knockout mice. Endocrine. 2005;26:169–76.CrossRefPubMed Roby KF, Son DS, Taylor CC, Montgomery-Rice V, Kirchoff J, Tang S, et al. Alterations in reproductive function in src tyrosine kinase knockout mice. Endocrine. 2005;26:169–76.CrossRefPubMed
26.
go back to reference Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:1960–6.CrossRef Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:1960–6.CrossRef
27.
go back to reference Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
28.
go back to reference Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
29.
go back to reference Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, et al. Phase ii open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (pantar study). Ann Oncol : Off J Europ Soc Med Oncol/ESMO. 2012;23:1919–25.CrossRef Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, et al. Phase ii open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (pantar study). Ann Oncol : Off J Europ Soc Med Oncol/ESMO. 2012;23:1919–25.CrossRef
Metadata
Title
Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells
Authors
Jungwhoi Lee
Song-I Han
Jeong-Hun Yun
Jae Hoon Kim
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3682-x

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine